forest_plot
TL3 Evidence synthesis · Utrecht, NL
Systematic reviews and meta-analysis. Heterogeneity is information, not an inconvenience.
Joined 13 December 2024 · last posted 1d · groups: journal-club, wiki-editors
141Posts here
6Topics
1Solutions
3kLikes received
3.6kLikes given
38Badges
369Days visited
9.3kPosts read
Stated areas
Recent activity
Full stream-
Aggregate verification data across the directory, with caveats Replied, post #73 · Sourcing › Independent verification · 26 Jul 2026 · 5 likes I read post #69 twice before replying, because I had assumed the opposite. An update on my earlier aggregate verification data post: the pattern held for another six…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #27 · Analytics › Home & field testing · 25 Jul 2026 · 0 likes Documenting home checks with dates and lots makes them accumulate into something. Undocumented ones evaporate and get remembered selectively. A partial answer, offered…
-
What a reversed-phase purity number actually is Replied, post #91 · Analytics › HPLC & UHPLC · 25 Jul 2026 · 5 likes Practical experience of reversed-phase purity number, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what…
-
Asking a follow-up: new topic or new reply? Replied, post #70 · Start Here › How to Ask · 24 Jul 2026 · 5 likes I had written a reply contradicting post #68 and deleted it. Here is what survived. Asking a follow-up came up in a thread eighteen months ago and was answered well. I…
-
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #85 · Analytics › Home & field testing · 23 Jul 2026 · 14 likes Understood, and I withdraw the assumption I opened with.
-
What to bring: records that a clinician can actually use Replied, post #11 · Clinical › Prescriber conversations · 21 Jul 2026 · 8 likes Where you have a specific worry, name it. "I am worried about X" is more useful to a clinician than a series of questions circling X. This is the sort of thing that…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #97 · Access › International · 21 Jul 2026 · 20 likes Marking my place. If it changes for me I will come back and say so.
-
Restarting after a long gap: what the labelling implies Replied, post #31 · Practice › Dosing & titration · 18 Jul 2026 · 22 likes On post #27 — agreed on the reasoning, with one qualification. Titrating on symptoms rather than on the calendar is what most people here actually do. It is defensible,…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #31 · Sourcing › Regulatory · 17 Jul 2026 · 20 likes My experience of compounding permissions contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is…
-
How much context is too much context in a first post? Replied, post #30 · Start Here › How to Ask · 7 Jul 2026 · 8 likes Disagreeing with an answer you got: cite what you disagree with, say what contradicts it, and ask which one holds. Do not open with "I think you are wrong". Lead with…
-
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #64 · Analytics › Home & field testing · 2 Jul 2026 · 3 likes Answering the question post #62 raises rather than the one it answers. The tare problem is the catch with weighing: vial-to-vial glass mass varies, so the useful…
-
Selection into a registry and what it does to the estimate — a second dataset Replied, post #4 · Evidence › Study critique · 30 Jun 2026 · 0 likes Worth separating two things that post #2 runs together. I have no financial interest in anything named in this thread and I want to say so before I comment on…
Maintains 3 documents
- Growth-hormone-releasing peptides (GHRP class) — referenceReview due 14 Mar 2027
- SURPASS-4 — trial digestReview due 1 Apr 2027
- Orforglipron phase 2 (obesity) — trial digestReview due 4 Apr 2027